Sagimet Biosciences (Nasdaq: SGMT) reported that its Board’s Compensation Committee approved an inducement grant in connection with the hiring of three employees. On August 17, 2026, the company granted an aggregate 260,700 stock options to purchase Series A common stock under Nasdaq Rule 5635(c)(4).
According to Sagimet, the options were granted as a material inducement to employment, with an exercise price equal to the closing market price on August 17, 2026. Each option has a 10-year term and vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
SGMT’s recent record includes a -1.17% reaction to FDA clearance and an 11.75% reaction to conferenc...
Analysis
SGMT’s recent record includes a -1.17% reaction to FDA clearance and an 11.75% reaction to conference participation. Against that mixed history, the grant’s vesting terms remain the key fact, with Net Selling as additional context.
Key Figures
New hires:3 employeesOption grant:260,700 stock optionsOption term:10 years+3 more
6 metrics
New hires3 employeesEmployment-related inducement grant
Option grant260,700 stock optionsAggregate grant on August 17, 2026
Option term10 yearsTerm of the granted options
Vesting period4 yearsOption vesting schedule
Initial vesting25%Vests on the one-year anniversary
Remaining vesting36 monthsMonthly vesting after the one-year anniversary
The company granted 34,300 stock options to two newly hired employees
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent SGMT news reactions diverged across catalysts, with positive clinical and corporate updates followed by both gains and declines.
Key Terms
inducement grant, nasdaq rule 5635(c)(4), vesting commencement date
3 terms
inducement grantfinancial
"approved that an inducement grant of 260,700 stock options in aggregate"
An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.
nasdaq rule 5635(c)(4)regulatory
"pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception"
NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.
vesting commencement datefinancial
"based on the employee’s employment commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.
The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to the acceptance of employment with Sagimet.
The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on August 17, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee’s employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to each individual’s continued service with Sagimet through the applicable vesting dates.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
What stock options did Sagimet Biosciences (NASDAQ: SGMT) grant on August 17, 2026?
Sagimet Biosciences granted an aggregate of 260,700 stock options on August 17, 2026 to three newly hired employees. According to Sagimet, these options allow purchase of Series A common stock as an employment inducement under Nasdaq Rule 5635(c)(4).
Who received the Sagimet Biosciences (SGMT) inducement stock option grant announced on August 17, 2026?
The inducement stock option grant was awarded to three newly hired employees of Sagimet Biosciences. According to Sagimet, these grants were a material component of each individual’s compensation package to encourage acceptance of employment with the company.
What are the vesting terms of the Sagimet Biosciences (SGMT) inducement options granted in August 2026?
The inducement options vest over four years: 25% vests on the one-year anniversary of each employee’s vesting commencement date, with the remaining shares vesting monthly over 36 months. According to Sagimet, vesting requires continued service through each vesting date.
What is the exercise price and term of the Sagimet Biosciences (SGMT) inducement stock options?
The options have a 10-year term and an exercise price equal to the closing price of Sagimet’s Series A common stock on August 17, 2026. According to Sagimet, this price is based on Nasdaq Global Market reporting for that date.
Why did Sagimet Biosciences use Nasdaq Rule 5635(c)(4) for the August 17, 2026 stock option grant?
Sagimet used the Nasdaq Rule 5635(c)(4) inducement grant exception to issue options as a material inducement to employment. According to Sagimet, the grant forms part of each new employee’s compensation package without requiring prior shareholder approval under that rule.
How might the Sagimet Biosciences (SGMT) inducement grant affect existing shareholders?
The grant authorizes 260,700 new options that could become shares if exercised, modestly increasing the total share count. According to Sagimet, these options are tied to employee retention and vest over four years, subject to continued service.
